Related Experiment Video
Updated: May 16, 2026
07:52
Analysis of Pulmonary Dendritic Cell Maturation and Migration during Allergic Airway Inflammation
Published on: July 23, 2012
PD-L2 modulates asthma severity by directly decreasing dendritic cell IL-12 production
I P Lewkowich1, S Lajoie, S L Stoffers
1Division of Cellular and Molecular Immunology, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA. Ian.Lewkowich@cchmc.org
Mucosal Immunology
|November 15, 2012
Summary
Programmed death 1 ligand 2 (PD-L2) exacerbates asthma by inhibiting interleukin-12 (IL-12) production independently of PD-1. Blocking PD-L2 reduces airway hyperresponsiveness in allergic asthma models.
Area of Science:
- Immunology
- Respiratory Medicine
- Allergy Research
Background:
- Conflicting findings exist regarding the role of programmed death 1 (PD-1) ligand 2 (PD-L2) and PD-1 in asthma.
- Understanding the specific mechanisms of PD-L2/PD-1 in asthma pathogenesis is crucial for developing targeted therapies.
Purpose of the Study:
- To investigate the role of PD-L2 expression in human asthma and its functional impact in a murine model of allergic airway inflammation.
- To elucidate the signaling pathway through which PD-L2 influences airway hyperresponsiveness (AHR) and associated cytokine production.
Main Methods:
- Analysis of PD-L2 expression in bronchial biopsies from human asthmatics.
- Assessment of PD-L2 and PD-1 blockade effects on allergen-induced AHR in mice.
- In vitro studies on dendritic cell (DC) stimulation and cytokine production (IL-12) upon PD-L2 engagement.
Main Results:
- PD-L2 expression in bronchial biopsies positively correlated with asthma severity.
- Allergen exposure increased PD-L2 on pulmonary myeloid DCs in mice, and PD-L2 blockade reduced AHR.
- PD-1 blockade did not affect AHR, indicating a PD-1-independent role for PD-L2.
- PD-L2 signaling inhibited IL-12 production by DCs, and IL-12 directly antagonized IL-13-induced gene expression.
Conclusions:
- Allergen-driven PD-L2 signaling exacerbates AHR in a PD-1-independent manner by limiting IL-12 secretion.
- This pathway represents a novel mechanism regulating IL-13 signaling and allergic airway inflammation.
- Targeting PD-L2 may offer a therapeutic strategy for managing allergic asthma.
Related Concept Videos
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
01:17Drugs Used in Lower Respiratory Disorders: Overview
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
01:24T Cell Types and Functions
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
01:26Asthma-II: Pathophysiology and Classification
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
01:28Asthma I: Introduction
Asthma is a chronic inflammatory disorder of the airways characterized by variable airflow obstruction and heightened bronchial responsiveness to a wide range of triggers. The underlying inflammation leads to airway swelling, mucus hypersecretion, and smooth muscle constriction, all of which narrow the airway lumen and impede airflow. Clinically, asthma presents with recurrent episodes of wheezing, shortness of breath, chest tightness, and coughing, symptoms that typically vary in intensity and...